Spoken Alpha
Alpha Cognition Inc.
Alpha Cognition Inc. develops and commercializes ZUNVEYL, an oral tablet for treating mild-to-moderate Alzheimer's disease, which launched in March 2025 and targets long-term care facilities. The company also has pre-clinical programs for combination therapies and other neurodegenerative conditions including mild traumatic brain injury and ALS.
Alpha Cognition Inc is a Healthcare company operating in Biotechnology with a $193.8M market cap.
ACOG missed consensus EPS by 0.0% in Q2 FY2026, reported Aug 12, 2026.
6 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ACOG.
$ curl https://api.spokenalpha.com/v1/companies/ACOGFAQ
Spoken Alpha indexes ACOG's earnings call transcripts at https://spokenalpha.com/companies/ACOG. Each call links to attributed speakers and parsed analyst Q&A. Alpha Cognition Inc.'s own investor relations page is at https://www.alphacognition.com/investors/.
Alpha Cognition Inc. (ACOG) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
Alpha Cognition Inc. (ACOG) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.40 | $-0.39 | -2.6% | $6.1M | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.32 | $-0.39 | +17.9% | $3.5M | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-0.31 | $-0.35 | +11.4% | $2.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.30 | $-0.43 | +30.2% | $2.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.65 | $-0.46 | -41.3% | $1.7M | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.20 | $-0.58 | +65.5% | $2.9M | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $-0.50 | $-0.48 | -4.2% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-14 | $-0.31 | $-1.00 | +69.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.25 | $-1.00 | +75.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-0.87 | — | — | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-28 | $-0.86 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-22 | $-0.74 | — | — | — | — | — | EODHD |
| Q1 FY2023 | 2023-05-30 | $-0.60 | — | — | — | — | — | EODHD |
| Q4 FY2022 | 2023-03-07 | $-1.25 | $-0.75 | -66.7% | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-27 | $-1.00 | $-1.25 | +20.0% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-24 | $-1.25 | $-1.25 | 0.0% | — | — | — | EODHD |
| Q1 FY2022 | 2022-04-27 | $-1.75 | $-1.50 | -16.7% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-29 | $-2.33 | — | — | — | — | — | EODHD |
Source: EODHD. ACOG reported actuals as published; sparse fields render as —.